Form 4: Palisade Bio CEO, CFO John David Finley Acquires Stock Options and Restricted Stock Units

CEO and CFO of Palisade Bio, John David Finley, reports acquisition of stock options and restricted stock units.

Summary

• On February 11, 2025, John David Finley, CEO and CFO of Palisade Bio, acquired 47,000 stock options with an exercise price of $1.13.
• These options vest in twelve equal quarterly installments over three years, starting May 11, 2025, contingent upon continuous service.
• Finley also acquired 40,000 Restricted Stock Units (RSUs), each representing one share of Palisade Bio's common stock.
• These RSUs vest in three equal annual installments beginning February 11, 2026, also contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, aligning management with shareholder interests through equity ownership. The vesting schedules promote long-term commitment.

Positives

• The acquisition of stock options and RSUs by the CEO and CFO aligns his interests with those of the shareholders.
• The vesting schedules incentivize long-term commitment and performance.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Palisade Bio's stock.
• If Finley's service is terminated, the unvested options and RSUs will be forfeited.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the equity grants suggest an expectation of future value creation.

Industry Context

Equity grants to executives are a common practice in the biotechnology industry to incentivize performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in publicly traded companies, particularly in the biotech sector.
• Vesting schedules are typically structured to incentivize long-term performance and retention, often over a 3-4 year period.
• The specific terms of the grants (e.g., vesting schedule, exercise price) would need to be compared to peer companies to assess their competitiveness.

Stakeholder Impact

• Shareholders: Aligns management's interests with shareholder value creation.
• Employees: May boost morale by demonstrating confidence in the company's future.
• Management: Incentivizes long-term performance and commitment.

Key Dates

Keywords

Palisade Bio, PALI, John David Finley, Stock Options, Restricted Stock Units, RSU, Form 4, Beneficial Ownership, CEO, CFO